Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Autoimmune Disorders

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 568 articles:
HTML format



Single Articles


    July 2022
  1. MANUEL ESCOBAR J, Cortese M, Edan G, Freedman MS, et al
    Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
    Mult Scler. 2022;28:1277-1285.
    PubMed     Abstract available


  2. W KOCH M, Mostert J, Repovic P, Bowen JD, et al
    Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
    Mult Scler. 2022;28:1286-1298.
    PubMed     Abstract available


  3. ANDERSEN JB, Wandall-Holm MF, Andersen PK, Sellebjerg F, et al
    Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort.
    Mult Scler. 2022;28:1239-1247.
    PubMed     Abstract available


  4. GIOVANNONI G, Singer BA, Issard D, Jack D, et al
    Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
    Mult Scler. 2022;28:1219-1228.
    PubMed     Abstract available


    June 2022
  5. HEMOND CC, Baek J, Ionete C, Reich DS, et al
    Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study.
    Mult Scler. 2022 Jun 24:13524585221102921. doi: 10.1177/13524585221102921.
    PubMed     Abstract available


  6. SCHIAVETTI I, Cordioli C, Stromillo ML, Teresa Ferro M, et al
    Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
    Mult Scler. 2022 Jun 23:13524585221102918. doi: 10.1177/13524585221102918.
    PubMed     Abstract available


  7. GARJANI A, Liu BJ, Allen CM, Gunzler DD, et al
    Decentralised clinical trials in multiple sclerosis research.
    Mult Scler. 2022 Jun 23:13524585221100401. doi: 10.1177/13524585221100401.
    PubMed     Abstract available


  8. MAAROUF A, Audoin B, Gherib S, El Mendili MM, et al
    Grey-matter sodium concentration as an individual marker of multiple sclerosis severity.
    Mult Scler. 2022 Jun 20:13524585221102587. doi: 10.1177/13524585221102587.
    PubMed     Abstract available


  9. GUERRERA G, Mandelli A, Finardi A, Orrico M, et al
    Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients.
    Mult Scler. 2022 Jun 20:13524585221102158. doi: 10.1177/13524585221102158.
    PubMed     Abstract available


  10. LAZZAROTTO A, Tonietto M, Poirion E, Battaglini M, et al
    Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: A multimodal and multicompartment imaging study.
    Mult Scler. 2022 Jun 16:13524585221096975. doi: 10.1177/13524585221096975.
    PubMed     Abstract available


  11. CHO EB, Yeo Y, Jung JH, Jeong SM, et al
    Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
    Mult Scler. 2022 Jun 13:13524585221096964. doi: 10.1177/13524585221096964.
    PubMed     Abstract available


  12. AL-LOUZI O, Manukyan S, Donadieu M, Absinta M, et al
    Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study.
    Mult Scler. 2022 Jun 8:13524585221097560. doi: 10.1177/13524585221097560.
    PubMed     Abstract available


  13. SCHMIERER K, Wiendl H, Oreja-Guevara C, Centonze D, et al
    Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
    Mult Scler. 2022 Jun 7:13524585221099413. doi: 10.1177/13524585221099413.
    PubMed    


  14. BRUNE S, Hogestol EA, de Rodez Benavent SA, Berg-Hansen P, et al
    Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221097296. doi: 10.1177/13524585221097296.
    PubMed     Abstract available


  15. LEAVITT VM, Dworkin JD, Buyukturkoglu K, Riley CS, et al
    Summary metrics of memory subnetwork functional connectivity alterations in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221099169. doi: 10.1177/13524585221099169.
    PubMed     Abstract available


  16. BEREK K, Hegen H, Hocher J, Auer M, et al
    Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.
    Mult Scler. 2022 Jun 2:13524585221097566. doi: 10.1177/13524585221097566.
    PubMed     Abstract available


  17. CARCAMO C, Ciampi E
    Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary.
    Mult Scler. 2022;28:1032-1033.
    PubMed    


  18. PIEHL F, Mathew T
    Low-dose rituximab should be used for treating MS in resource-limited settings: Yes.
    Mult Scler. 2022;28:1028-1029.
    PubMed    


  19. MATEEN FJ
    Low-dose rituximab should be used for treating MS in resource-limited settings: No.
    Mult Scler. 2022;28:1030-1032.
    PubMed    


  20. WRIGHT S
    MOG antibody-associated longitudinal extensive myelitis after Oxford-Astra Zeneca's COVID-19 vaccination.
    Mult Scler. 2022;28:1163.
    PubMed    


  21. DAMS L, Kraemer M, Becker J
    MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination.
    Mult Scler. 2022;28:1159-1162.
    PubMed     Abstract available


  22. RINALDI V, Bellucci G, Romano A, Bozzao A, et al
    ADEM after ChAdOx1 nCoV-19 vaccine: A case report.
    Mult Scler. 2022;28:1151-1154.
    PubMed     Abstract available


  23. PODDA J, Tacchino A, Pedulla L, Monti Bragadin M, et al
    Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.
    Mult Scler. 2022;28:1009-1019.
    PubMed     Abstract available


    May 2022
  24. COFRE LIZAMA LE, Strik M, Van der Walt A, Kilpatrick TJ, et al
    Gait stability reflects motor tracts damage at early stages of multiple sclerosis.
    Mult Scler. 2022 May 21:13524585221094464. doi: 10.1177/13524585221094464.
    PubMed     Abstract available


  25. FADDA G, Waters P, Woodhall M, Brown RA, et al
    Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.
    Mult Scler. 2022 May 17:13524585221093789. doi: 10.1177/13524585221093789.
    PubMed     Abstract available


  26. GONZALEZ-MARTINEZ A, Bose G, Chitnis T
    Anti-CGRP therapies for migraine in multiple sclerosis patients.
    Mult Scler. 2022 May 14:13524585221096353. doi: 10.1177/13524585221096353.
    PubMed    


  27. SCHWARZ T, Otto C, Jones TC, Pache F, et al
    Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
    Mult Scler. 2022 May 14:13524585221094478. doi: 10.1177/13524585221094478.
    PubMed     Abstract available


  28. LEUNG MW, Bazelier MT, Souverein PC, Uitdehaag BM, et al
    Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.
    Mult Scler. 2022 May 14:13524585221094218. doi: 10.1177/13524585221094218.
    PubMed     Abstract available


  29. ALMRAMHI MM, Storm CS, Kia DA, Coneys R, et al
    The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study.
    Mult Scler. 2022 May 14:13524585221092644. doi: 10.1177/13524585221092644.
    PubMed     Abstract available


  30. CHIARAVALLOTI ND, DeLuca J, Salter A, Amato MP, et al
    The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.
    Mult Scler. 2022 May 9:13524585221088190. doi: 10.1177/13524585221088190.
    PubMed     Abstract available


  31. MANGLANI HR, Fisher ME, Duraney EJ, Nicholas JA, et al
    A promising cognitive screener in multiple sclerosis: The NIH toolbox cognition battery concords with gold standard neuropsychological measures.
    Mult Scler. 2022 May 9:13524585221088731. doi: 10.1177/13524585221088731.
    PubMed     Abstract available


  32. HYUN JW, Lee HL, Park J, Kim J, et al
    Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.
    Mult Scler. 2022;28:989-992.
    PubMed     Abstract available


  33. VALSASINA P, Gobbi C, Zecca C, Rovira A, et al
    Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis.
    Mult Scler. 2022;28:885-899.
    PubMed     Abstract available


  34. RENSEL M, Zabeti A, Mealy MA, Cimbora D, et al
    Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for 4 years in the N-MOmentum trial.
    Mult Scler. 2022;28:925-932.
    PubMed     Abstract available


  35. ROSENSTEIN I, Axelsson M, Novakova L, Blennow K, et al
    Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
    Mult Scler. 2022;28:872-884.
    PubMed     Abstract available



  36. ACTRIMS Forum 2022.
    Mult Scler. 2022;28.
    PubMed    


    April 2022
  37. SPRENGER T, Kappos L, Sormani MP, Miller AE, et al
    Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
    Mult Scler. 2022 Apr 29:13524585221089534. doi: 10.1177/13524585221089534.
    PubMed     Abstract available


  38. DEGRAEVE B, Sequeira H, Mecheri H, Lenne B, et al
    Corpus callosum damage to account for cognitive, affective, and social-cognitive dysfunctions in multiple sclerosis: A model of callosal disconnection syndrome?
    Mult Scler. 2022 Apr 27:13524585221091067. doi: 10.1177/13524585221091067.
    PubMed     Abstract available


  39. MANZANO GS, Rice DR, Klawiter EC, Matiello M, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Apr 27:13524585221092309. doi: 10.1177/13524585221092309.
    PubMed     Abstract available


  40. ZABALZA A, Arrambide G, Otero-Romero S, Pappolla A, et al
    Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
    Mult Scler. 2022 Apr 27:13524585221089540. doi: 10.1177/13524585221089540.
    PubMed     Abstract available


  41. SIMONEAU G, Pellegrini F, Debray TP, Rouette J, et al
    Recommendations for the use of propensity score methods in multiple sclerosis research.
    Mult Scler. 2022 Apr 6:13524585221085733. doi: 10.1177/13524585221085733.
    PubMed     Abstract available


  42. CREE BA, Arnold DL, Fox RJ, Gold R, et al
    Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Mult Scler. 2022 Apr 5:13524585221083194. doi: 10.1177/13524585221083194.
    PubMed     Abstract available


  43. KALINCIK T, Kister I, Bacon TE, Malpas CB, et al
    Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
    Mult Scler. 2022 Apr 3:13524585221084577. doi: 10.1177/13524585221084577.
    PubMed     Abstract available


  44. MOCCIA M, Affinito G, Ronga B, Giordana R, et al
    Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).
    Mult Scler. 2022;28:597-607.
    PubMed     Abstract available


  45. GRATCH D, Zhovtis Ryerson L
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary.
    Mult Scler. 2022;28:695-696.
    PubMed    


  46. INES CIPLEA A, Kurzeja A, Thiel S, Haben S, et al
    Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.
    Mult Scler. 2022 Apr 1:13524585221083982. doi: 10.1177/13524585221083982.
    PubMed     Abstract available


  47. TZANETAKOS D, Tzartos JS, Vakrakou AG, Breza M, et al
    Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study.
    Mult Scler. 2022;28:718-729.
    PubMed     Abstract available


  48. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter.
    Mult Scler. 2022;28:697-706.
    PubMed     Abstract available


  49. ALY L, Strauss EM, Feucht N, Weiss I, et al
    Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders.
    Mult Scler. 2022;28:522-531.
    PubMed     Abstract available


  50. ABDEL-MANNAN O, Klein A, Bachar Zipori A, Ben-Sira L, et al
    Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder.
    Mult Scler. 2022;28:676-679.
    PubMed     Abstract available


  51. ROTSTEIN DL
    Radiologically isolated syndrome and the possibility of preclinical disease activity in aquaporin-4 antibody NMOSD.
    Mult Scler. 2022;28:679-680.
    PubMed    


  52. KIM KH, Kim SH, Park NY, Hyun JW, et al
    Reappraisal of CSF-specific oligoclonal bands in Asia.
    Mult Scler. 2022;28:665-668.
    PubMed     Abstract available


  53. KUHLE J, Daizadeh N, Benkert P, Maceski A, et al
    Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
    Mult Scler. 2022;28:573-582.
    PubMed     Abstract available


  54. BAJRAMI A, Magliozzi R, Pisani AI, Pizzini FB, et al
    Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS.
    Mult Scler. 2022;28:550-560.
    PubMed     Abstract available


  55. KIM H, Lee EJ, Kim S, Choi LK, et al
    Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder.
    Mult Scler. 2022;28:512-521.
    PubMed     Abstract available


  56. VALENTINE TR, Alschuler KN, Ehde DM, Kratz AL, et al
    Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis.
    Mult Scler. 2022;28:620-631.
    PubMed     Abstract available


    March 2022
  57. GASPERI C, Hapfelmeier A, Schneider A, Kuhn KA, et al
    Association of pregnancies with risk of multiple sclerosis.
    Mult Scler. 2022 Mar 18:13524585221080542. doi: 10.1177/13524585221080542.
    PubMed     Abstract available


  58. PORTACCIO E, Pasto L, Razzolini L, Moiola L, et al
    Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
    Mult Scler. 2022 Mar 16:13524585221079598. doi: 10.1177/13524585221079598.
    PubMed     Abstract available


  59. RIEMENSCHNEIDER M, Hvid LG, Ringgaard S, Nygaard MKE, et al
    Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
    Mult Scler. 2022 Mar 16:13524585221079200. doi: 10.1177/13524585221079200.
    PubMed     Abstract available


  60. CARLSON A, McGinley MP
    Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.
    Mult Scler. 2022 Mar 16:13524585221081985. doi: 10.1177/13524585221081985.
    PubMed    


  61. LIANG G, Zhu F, Mirza AI, Bar-Or A, et al
    Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases.
    Mult Scler. 2022 Mar 16:13524585221079533. doi: 10.1177/13524585221079533.
    PubMed     Abstract available


  62. JACOBS BM, Watson C, Marshall C, Noyce A, et al
    No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 16:13524585221075744. doi: 10.1177/13524585221075744.
    PubMed    


  63. DALGAS U, Stenager E, Hvid LG
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: Commentary.
    Mult Scler. 2022 Mar 16:13524585211072702. doi: 10.1177/13524585211072702.
    PubMed    


  64. MOTL RW, Sandroff BM
    Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect-Yes.
    Mult Scler. 2022 Mar 16:13524585211061651. doi: 10.1177/13524585211061651.
    PubMed    


  65. HEESEN C, Rosenkranz SC
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No.
    Mult Scler. 2022 Mar 16:13524585211064968. doi: 10.1177/13524585211064968.
    PubMed    


  66. WENDEL EM, Bertolini A, Kousoulos L, Rauchenzauner M, et al
    Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome.
    Mult Scler. 2022 Mar 14:13524585221081090. doi: 10.1177/13524585221081090.
    PubMed     Abstract available


  67. BSTEH G, Hegen H, Berek K, Altmann P, et al
    Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
    Mult Scler. 2022 Mar 12:13524585221079744. doi: 10.1177/13524585221079744.
    PubMed     Abstract available


  68. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 12:13524585221079044. doi: 10.1177/13524585221079044.
    PubMed    


  69. GARTNER J, Hauser SL, Bar-Or A, Montalban X, et al
    Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
    Mult Scler. 2022 Mar 10:13524585221078825. doi: 10.1177/13524585221078825.
    PubMed     Abstract available


  70. ARNOLD DL, Piani-Meier D, Bar-Or A, Benedict RH, et al
    Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
    Mult Scler. 2022 Mar 9:13524585221076717. doi: 10.1177/13524585221076717.
    PubMed     Abstract available


  71. BEBO BF JR, Allegretta M, Landsman D, Zackowski KM, et al
    Pathways to cures for multiple sclerosis: A research roadmap.
    Mult Scler. 2022;28:331-345.
    PubMed     Abstract available


  72. HAUSER SL, Cross AH, Winthrop K, Wiendl H, et al
    Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
    Mult Scler. 2022 Mar 1:13524585221079731. doi: 10.1177/13524585221079731.
    PubMed     Abstract available


  73. PITTOCK SJ, Fujihara K, Palace J, Berthele A, et al
    Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
    Mult Scler. 2022;28:480-486.
    PubMed     Abstract available


  74. PORTACCIO E, Tudisco L, Pasto L, Razzolini L, et al
    Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.
    Mult Scler. 2022;28:472-479.
    PubMed     Abstract available


  75. VAVASOUR IM, Sun P, Graf C, Yik JT, et al
    Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging.
    Mult Scler. 2022;28:418-428.
    PubMed     Abstract available


    February 2022
  76. TUR C, Dubessy AL, Otero-Romero S, Amato MP, et al
    The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
    Mult Scler. 2022 Feb 23:13524585211069068. doi: 10.1177/13524585211069068.
    PubMed     Abstract available


  77. SHAFIN N, Ismail CAN, Mustafa MZ, Ghani N, et al
    Thematic analysis of multiple sclerosis research by enhanced strategic diagram.
    Mult Scler. 2022 Feb 15:13524585221075542. doi: 10.1177/13524585221075542.
    PubMed     Abstract available



  78. Erratum to "Assessing diagnosis disclosure and concealment in multiple sclerosis: building a framework for moving forward".
    Mult Scler. 2022 Feb 11:13524585221079450. doi: 10.1177/13524585221079450.
    PubMed    


  79. BECK ES, Maranzano J, Luciano NJ, Parvathaneni P, et al
    Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis.
    Mult Scler. 2022 Feb 10:13524585211069167. doi: 10.1177/13524585211069167.
    PubMed     Abstract available


  80. RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Patten S, et al
    Productivity loss among people with early multiple sclerosis: A Canadian study.
    Mult Scler. 2022 Feb 9:13524585211069070. doi: 10.1177/13524585211069070.
    PubMed     Abstract available


  81. O'MAHONY J, Banwell B, Laporte A, Brown A, et al
    The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents.
    Mult Scler. 2022 Feb 7:13524585211061521. doi: 10.1177/13524585211061521.
    PubMed     Abstract available


  82. HOLM HANSEN R, Hojsgaard Chow H, Talbot J, Buhelt S, et al
    Peripheral helper T cells in the pathogenesis of multiple sclerosis.
    Mult Scler. 2022 Feb 3:13524585211067696. doi: 10.1177/13524585211067696.
    PubMed     Abstract available


  83. DOBSON R, Chung K
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary.
    Mult Scler. 2022;28:326-327.
    PubMed    


  84. COYLE PK, Syritsyna O
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Yes.
    Mult Scler. 2022;28:183-185.
    PubMed    


  85. BERMEL RA
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - No.
    Mult Scler. 2022;28:185-187.
    PubMed    


  86. FOX RJ, Tintore M
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Commentary.
    Mult Scler. 2022;28:187-188.
    PubMed    


  87. HILLERT J, Tsai JA, Nouhi M, Glaser A, et al
    A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
    Mult Scler. 2022;28:237-246.
    PubMed     Abstract available


  88. ZHENG Y, Dudman J, Chen JT, Mahajan KR, et al
    Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.
    Mult Scler. 2022;28:198-205.
    PubMed     Abstract available


  89. PFEUFFER S, Rolfes L, Hackert J, Kleinschnitz K, et al
    Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
    Mult Scler. 2022;28:257-268.
    PubMed     Abstract available


    January 2022
  90. LIAO CM, Kuo WY, Kung PT, Chuan CH, et al
    Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan.
    Mult Scler. 2022 Jan 25:13524585211061341. doi: 10.1177/13524585211061341.
    PubMed     Abstract available


  91. NAKAMURA K, Zheng Y, Ontaneda D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yes.
    Mult Scler. 2022 Jan 22:13524585211066313. doi: 10.1177/13524585211066313.
    PubMed    


  92. MUHLAU M
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No.
    Mult Scler. 2022 Jan 22:13524585211063622. doi: 10.1177/13524585211063622.
    PubMed    


  93. ROVIRA A, Pareto D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis - Commentary.
    Mult Scler. 2022 Jan 22:13524585211069363. doi: 10.1177/13524585211069363.
    PubMed    


  94. KEVER A, Riley CS, Leavitt VM
    Diagnosis concealment is associated with psychosocial outcomes in persons with multiple sclerosis.
    Mult Scler. 2022 Jan 16:13524585211070496. doi: 10.1177/13524585211070496.
    PubMed     Abstract available


  95. P MOSS B, Miller DM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward.
    Mult Scler. 2022 Jan 11:13524585211069668. doi: 10.1177/13524585211069668.
    PubMed    


  96. BELVISI D, Canevelli M, Marfia GA, Ferraro E, et al
    Response to "Frailty in multiple sclerosis: A closer look at the deficit accumulation framework".
    Mult Scler. 2022 Jan 8:13524585211068150. doi: 10.1177/13524585211068150.
    PubMed    


  97. ZIAEI A, Lavery AM, Shao XM, Adams C, et al
    Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.
    Mult Scler. 2022 Jan 8:13524585211069926. doi: 10.1177/13524585211069926.
    PubMed     Abstract available


  98. VAN KEMPEN ZL, Hogenboom L, Killestein J
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
    Mult Scler. 2022 Jan 7:13524585211064441. doi: 10.1177/13524585211064441.
    PubMed    


  99. COHEN JA, Bermel RA, Grossman CI, Hersh CM, et al
    Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
    Mult Scler. 2022 Jan 7:13524585211061343. doi: 10.1177/13524585211061343.
    PubMed     Abstract available


  100. THOMPSON AJ, Carroll W, Ciccarelli O, Comi G, et al
    Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.
    Mult Scler. 2022;28:16-28.
    PubMed     Abstract available


  101. TARDO L, Wang C, Rajaram V, Greenberg BM, et al
    Pediatric paraneoplastic neuromyelitis optica spectrum disorder associated with ovarian teratoma.
    Mult Scler. 2022;28:160-163.
    PubMed     Abstract available


  102. ABDEL-MANNAN O, Hacohen Y
    Aquaporin-4 antibody neuromyelitis optica spectrum disorder: A paraneoplastic disease?
    Mult Scler. 2022;28:163-164.
    PubMed    


  103. TAJFIROUZ D, Padungkiatsagul T, Beres S, Moss HE, et al
    Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder.
    Mult Scler. 2022;28:149-153.
    PubMed     Abstract available


  104. COMABELLA M, Clarke MA, Schaedelin S, Tintore M, et al
    CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.
    Mult Scler. 2022;28:71-81.
    PubMed     Abstract available


  105. SIGNORIELLO E, Lus G, Bonavita S, Lanzillo R, et al
    Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
    Mult Scler. 2022;28:93-101.
    PubMed     Abstract available


    December 2021
  106. GAITAN MI, Sanchez M, Farez MF, Fiol MP, et al
    The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina.
    Mult Scler. 2021 Dec 31:13524585211067521. doi: 10.1177/13524585211067521.
    PubMed     Abstract available


  107. BERNARDI G, Biagioli T, Malpassi P, De Michele T, et al
    The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study.
    Mult Scler. 2021 Dec 30:13524585211064121. doi: 10.1177/13524585211064121.
    PubMed     Abstract available


  108. CAVACO S, Ferreira I, Moreira I, Santos E, et al
    Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review.
    Mult Scler. 2021 Dec 30:13524585211066598. doi: 10.1177/13524585211066598.
    PubMed     Abstract available


  109. VAN KEMPEN ZL, Toorop AA, Sellebjerg F, Giovannoni G, et al
    Extended dosing of monoclonal antibodies in multiple sclerosis.
    Mult Scler. 2021 Dec 24:13524585211065711. doi: 10.1177/13524585211065711.
    PubMed     Abstract available


  110. NG HS, Zhu F, Kingwell E, Zhao Y, et al
    Disease-modifying drugs for multiple sclerosis and subsequent health service use.
    Mult Scler. 2021 Dec 24:13524585211063403. doi: 10.1177/13524585211063403.
    PubMed     Abstract available


  111. FERNANDEZ RS, Crivelli L, Pedreira ME, Allegri RF, et al
    Computational basis of decision-making impairment in multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211059308. doi: 10.1177/13524585211059308.
    PubMed     Abstract available


  112. ZANOTTO T, Lynch SG, Hausdorff JM, Sosnoff JJ, et al
    Frailty in multiple sclerosis: A closer look at the deficit accumulation framework.
    Mult Scler. 2021 Dec 21:13524585211061332. doi: 10.1177/13524585211061332.
    PubMed    


  113. ROLFES L, Meuth SG
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
    Mult Scler. 2021 Dec 21:13524585211055593. doi: 10.1177/13524585211055593.
    PubMed    


  114. TOOROP AA, Rispens T, Strijbis EM, van Oosten BW, et al
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211052168. doi: 10.1177/13524585211052168.
    PubMed     Abstract available


  115. JANUEL E, De Seze J, Vermersch P, Maillart E, et al
    Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
    Mult Scler. 2021 Dec 21:13524585211049737. doi: 10.1177/13524585211049737.
    PubMed     Abstract available


  116. COLES AJ, Jones JL, Vermersch P, Traboulsee A, et al
    Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
    Mult Scler. 2021 Dec 9:13524585211061335. doi: 10.1177/13524585211061335.
    PubMed     Abstract available


  117. ROVIRA A, Corral JF, Auger C, Valverde S, et al
    Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients.
    Mult Scler. 2021 Dec 3:13524585211061339. doi: 10.1177/13524585211061339.
    PubMed     Abstract available


  118. LEEKOFF M, Culpepper W, Jin S, Lee-Wilk T, et al
    Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study.
    Mult Scler. 2021 Dec 2:13524585211058361. doi: 10.1177/13524585211058361.
    PubMed     Abstract available


  119. VAN KEMPEN ZL, Killestein J, Hartung HP
    Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients.
    Mult Scler. 2021;27:2123-2125.
    PubMed    


  120. NOURBAKHSH B
    Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
    Mult Scler. 2021;27:2290.
    PubMed    


  121. LEHMANN H, Zveik O, Levin N, Brill L, et al
    Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses.
    Mult Scler. 2021;27:2232-2239.
    PubMed     Abstract available


  122. OH J, Suthiphosuwan S, Sati P, Absinta M, et al
    Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS.
    Mult Scler. 2021;27:2199-2208.
    PubMed     Abstract available


    November 2021
  123. SARKAR P, Redondo J, Hares K, Bailey S, et al
    Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.
    Mult Scler. 2021 Nov 29:13524585211060686. doi: 10.1177/13524585211060686.
    PubMed     Abstract available


  124. OTERO-ROMERO S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, et al
    Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.
    Mult Scler. 2021 Nov 29:13524585211053001. doi: 10.1177/13524585211053001.
    PubMed     Abstract available


  125. KIRA JI, Nakahara J, Sazonov DV, Kurosawa T, et al
    Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
    Mult Scler. 2021 Nov 17:13524585211055934. doi: 10.1177/13524585211055934.
    PubMed     Abstract available


  126. SCHORR EM, Kurz D, Rossi KC, Zhang M, et al
    Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.
    Mult Scler. 2021 Nov 17:13524585211051316. doi: 10.1177/13524585211051316.
    PubMed     Abstract available


  127. MARRIE RA, McKay K
    Administrative data for observational research in multiple sclerosis: Opportunities and challenges.
    Mult Scler. 2021 Nov 17:13524585211055787. doi: 10.1177/13524585211055787.
    PubMed    


  128. MAUBEUGE N, Deloire MS, Brochet B, Charre-Morin J, et al
    Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.
    Mult Scler. 2021 Nov 12:13524585211054006. doi: 10.1177/13524585211054006.
    PubMed     Abstract available


  129. MOUMDJIAN L, Moens B, Van Wijmeersh B, Leman M, et al
    Application of step and beat alignment approaches and its effect on gait in progressive multiple sclerosis with severe cerebellar ataxia: A proof of concept case study.
    Mult Scler. 2021 Nov 2:13524585211054000. doi: 10.1177/13524585211054000.
    PubMed     Abstract available


  130. CREE BA, Bennett JL, Kim HJ, Weinshenker BG, et al
    Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
    Mult Scler. 2021;27:2052-2061.
    PubMed     Abstract available


  131. DAHLKE F, Arnold DL, Aarden P, Ganjgahi H, et al
    Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
    Mult Scler. 2021;27:2062-2076.
    PubMed     Abstract available


    October 2021
  132. MISICKA E, Davis MF, Kim W, Brugger SW, et al
    A higher burden of multiple sclerosis genetic risk confers an earlier onset.
    Mult Scler. 2021 Oct 28:13524585211053155. doi: 10.1177/13524585211053155.
    PubMed     Abstract available


  133. PONCET-MEGEMONT L, Pereira B, Rollot F, Sormani MP, et al
    Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.
    Mult Scler. 2021 Oct 26:13524585211052400. doi: 10.1177/13524585211052400.
    PubMed     Abstract available


  134. BERGAMASCHI R, Montomoli C
    Air pollution is a risk factor for multiple sclerosis - Yes.
    Mult Scler. 2021 Oct 22:13524585211035953. doi: 10.1177/13524585211035953.
    PubMed    


  135. DELGADO-GARCIA G, Corona T
    Air pollution is a risk factor for multiple sclerosis - No.
    Mult Scler. 2021 Oct 22:13524585211026875. doi: 10.1177/13524585211026875.
    PubMed    


  136. SAHRAIAN MA
    Air pollution is a risk factor for multiple sclerosis - Commentary.
    Mult Scler. 2021 Oct 22:13524585211046352. doi: 10.1177/13524585211046352.
    PubMed    


  137. ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
    Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
    Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
    PubMed     Abstract available


  138. UHER T, Havrdova EK, Benkert P, Bergsland N, et al
    Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
    Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
    PubMed     Abstract available


  139. VILLOSLADA P
    Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
    Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.
    PubMed    


  140. WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
    Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
    Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
    PubMed     Abstract available


  141. SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
    Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
    Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
    PubMed     Abstract available


  142. BOSMA AR, Murley C, Aspling J, Hillert J, et al
    Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
    Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
    PubMed     Abstract available


  143. BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
    Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
    Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
    PubMed     Abstract available


  144. GROTHE M, Ellenberger D, von Podewils F, Stahmann A, et al
    Epilepsy as a predictor of disease progression in multiple sclerosis.
    Mult Scler. 2021 Oct 1:13524585211046739. doi: 10.1177/13524585211046739.
    PubMed     Abstract available


  145. SANDROFF BM, Motl RW, Amato MP, Brichetto G, et al
    Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.
    Mult Scler. 2021 Oct 1:13524585211048397. doi: 10.1177/13524585211048397.
    PubMed     Abstract available


  146. BSTEH G, Durauer S, Assar H, Hegen H, et al
    Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
    Mult Scler. 2021 Oct 1:13524585211049391. doi: 10.1177/13524585211049391.
    PubMed     Abstract available


  147. GEORGIEVA ZG, Dffinger R, Kumararatne D, Coles AJ, et al
    Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2021 Oct 1:13524585211046786. doi: 10.1177/13524585211046786.
    PubMed     Abstract available


  148. CAMERON MH, Hildebrand A, Hugos CL, Judd GI, et al
    Free From Falls education and exercise program for reducing falls in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2021 Oct 1:13524585211046898. doi: 10.1177/13524585211046898.
    PubMed     Abstract available


  149. ROBERS MV, Chan C, Vajdi B, Chiong-Rivero H, et al
    Hypertension and hypertension severity in Hispanics/Latinx with MS.
    Mult Scler. 2021;27:1894-1901.
    PubMed     Abstract available


  150. ELKJAER ML, Frisch T, Tonazzolli A, Rottger R, et al
    Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions.
    Mult Scler. 2021;27:1829-1837.
    PubMed     Abstract available


  151. KOCH MW, Mostert JP, Uitdehaag B, Cutter G, et al
    A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
    Mult Scler. 2021;27:1864-1874.
    PubMed     Abstract available


  152. KOCH MW, Metz L, Cutter G
    An enrichment strategy for clinical trials in SPMS.
    Mult Scler. 2021;27:1884-1893.
    PubMed     Abstract available


    September 2021
  153. BUSSAS M, Grahl S, Pongratz V, Berthele A, et al
    Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
    Mult Scler. 2021 Sep 30:13524585211044957. doi: 10.1177/13524585211044957.
    PubMed     Abstract available


  154. KEVER A, Leavitt VM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey.
    Mult Scler. 2021 Sep 9:13524585211037581. doi: 10.1177/13524585211037581.
    PubMed     Abstract available


  155. KRYSKO KM, Anderson A, Singh J, McPolin K, et al
    Risk factors for peripartum depression in women with multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211041108. doi: 10.1177/13524585211041108.
    PubMed     Abstract available


  156. WOJCIK C, Jaworski M 3rd, Dwyer MG, Youngs M, et al
    Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211044672. doi: 10.1177/13524585211044672.
    PubMed     Abstract available


  157. TREMLETT H, Okuda DT, Lebrun-Frenay C
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No.
    Mult Scler. 2021 Sep 8:13524585211035951. doi: 10.1177/13524585211035951.
    PubMed    


  158. GNANAPAVAN S
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Yes.
    Mult Scler. 2021 Sep 8:13524585211040223. doi: 10.1177/13524585211040223.
    PubMed    


  159. MAKHANI N
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Commentary.
    Mult Scler. 2021 Sep 8:13524585211044951. doi: 10.1177/13524585211044951.
    PubMed    


  160. BRADLEY L
    Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
    Mult Scler. 2021 Sep 5:13524585211035737. doi: 10.1177/13524585211035737.
    PubMed     Abstract available


  161. ENZINGER C
    Slowly expanding lesions are a marker of progressive multiple sclerosis - Commentary.
    Mult Scler. 2021 Sep 3:13524585211040225. doi: 10.1177/13524585211040225.
    PubMed    


  162. HARTUNG HP, Meuth SG, Thompson AJ
    Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
    Mult Scler. 2021;27:1473-1476.
    PubMed    


  163. GOLD R, Arnold DL, Bar-Or A, Fox RJ, et al
    Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Mult Scler. 2021 Sep 1:13524585211037909. doi: 10.1177/13524585211037909.
    PubMed     Abstract available


    August 2021
  164. CONWAY DS, Marck CH
    Comorbidities require special attention in minorities with multiple sclerosis.
    Mult Scler. 2021 Aug 27:13524585211037578. doi: 10.1177/13524585211037578.
    PubMed    


  165. BLASCHKE SJ, Ellenberger D, Flachenecker P, Hellwig K, et al
    Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.
    Mult Scler. 2021 Aug 27:13524585211039753. doi: 10.1177/13524585211039753.
    PubMed     Abstract available


  166. COHEN JA, Cameron MH, Goldman MD, Goodman AD, et al
    A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
    Mult Scler. 2021 Aug 27:13524585211035333. doi: 10.1177/13524585211035333.
    PubMed     Abstract available


  167. GUERRA T, Bollo L, Trojano M, Iaffaldano P, et al
    Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
    Mult Scler. 2021 Aug 27:13524585211030214. doi: 10.1177/13524585211030214.
    PubMed     Abstract available


  168. ALONSO R, Galleguillos L
    Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
    Mult Scler. 2021 Aug 27:13524585211039750. doi: 10.1177/13524585211039750.
    PubMed    


  169. ABBADESSA G, Lavorgna L, Treaba CA, Bonavita S, et al
    Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039111. doi: 10.1177/13524585211039111.
    PubMed     Abstract available


  170. BUTLER PAGNOTTI R, Hua LH, Miller JB
    Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039112. doi: 10.1177/13524585211039112.
    PubMed     Abstract available


  171. TILLAUT H, Degremont A, Kerbrat S, Roux J, et al
    Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies.
    Mult Scler. 2021 Aug 19:13524585211035376. doi: 10.1177/13524585211035376.
    PubMed     Abstract available


  172. ROMMER PS, Bsteh G, Berger T, Zettl UK, et al
    SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?
    Mult Scler. 2021 Aug 13:13524585211039128. doi: 10.1177/13524585211039128.
    PubMed    


  173. MARCHESI O, Bonacchi R, Valsasina P, Preziosa P, et al
    Functional and structural MRI correlates of executive functions in multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211033184. doi: 10.1177/13524585211033184.
    PubMed     Abstract available


  174. CLAFLIN SB, Campbell JA, Mason DF, Kalincik T, et al
    The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211035948. doi: 10.1177/13524585211035948.
    PubMed     Abstract available


  175. WEINSTOCK-GUTTMAN B, Bermel R, Cutter G, Freedman MS, et al
    Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
    Mult Scler. 2021 Aug 12:13524585211035740. doi: 10.1177/13524585211035740.
    PubMed     Abstract available


  176. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study.
    Mult Scler. 2021 Aug 11:13524585211034826. doi: 10.1177/13524585211034826.
    PubMed     Abstract available


  177. AYADI N, Oertel FC, Asseyer S, Rust R, et al
    Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2021 Aug 11:13524585211032801. doi: 10.1177/13524585211032801.
    PubMed     Abstract available


  178. ZHENG F, Li Y, Zhuo Z, Duan Y, et al
    Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2021 Aug 11:13524585211032800. doi: 10.1177/13524585211032800.
    PubMed     Abstract available


  179. COMI G, Dadon Y, Sasson N, Steinerman JR, et al
    CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Aug 11:13524585211032803. doi: 10.1177/13524585211032803.
    PubMed     Abstract available


  180. PANDIT L
    Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines.
    Mult Scler. 2021;27:1320-1322.
    PubMed    


  181. KANINIA S, Grammatikos A, Urankar K, Renowden SA, et al
    CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant.
    Mult Scler. 2021;27:1464-1467.
    PubMed     Abstract available


    July 2021
  182. SORMANI MP, Schiavetti I, Landi D, Carmisciano L, et al
    SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
    Mult Scler. 2021 Jul 30:13524585211035318. doi: 10.1177/13524585211035318.
    PubMed     Abstract available


  183. ROTSTEIN D, Maxwell C, Tu K, Gatley J, et al
    High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis.
    Mult Scler. 2021 Jul 30:13524585211031791. doi: 10.1177/13524585211031791.
    PubMed     Abstract available


  184. PITTERI M, Magliozzi R, Nicholas R, Ziccardi S, et al
    Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients.
    Mult Scler. 2021 Jul 30:13524585211032510. doi: 10.1177/13524585211032510.
    PubMed     Abstract available


  185. UHR L, Mateen FJ
    COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey.
    Mult Scler. 2021 Jul 27:13524585211030647. doi: 10.1177/13524585211030647.
    PubMed     Abstract available


  186. LAURSON-DOUBE J, Rijke N, Helme A, Baneke P, et al
    Ethical use of off-label disease-modifying therapies for multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211030207. doi: 10.1177/13524585211030207.
    PubMed     Abstract available


  187. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211031801. doi: 10.1177/13524585211031801.
    PubMed     Abstract available


  188. LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
    Risk of depression in multiple sclerosis across disease-modifying therapies.
    Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
    PubMed     Abstract available


  189. BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
    Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
    PubMed     Abstract available


  190. MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
    A smartphone sensor-based digital outcome assessment of multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
    PubMed     Abstract available


  191. HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
    Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
    Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
    PubMed     Abstract available


  192. WIJERATNE T, Carroll W
    World Brain Day 2021: Global campaign to stop multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.
    PubMed    


  193. HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
    Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
    Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
    PubMed     Abstract available


  194. VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
    Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
    Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
    PubMed     Abstract available


  195. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
    Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
    PubMed     Abstract available


  196. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
    Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
    Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
    PubMed     Abstract available


  197. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
    Performance validity in outpatients with multiple sclerosis and cognitive complaints.
    Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
    PubMed     Abstract available


  198. ESHAGHI A
    Towards an objective classification of multiple sclerosis.
    Mult Scler. 2021;27:1151-1152.
    PubMed    


  199. CALDITO NG, O'Leary S, Stuve O
    Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Mult Scler. 2021;27:1306-1308.
    PubMed     Abstract available


  200. MARRIE RA, Patel R, Bernstein CN, Bolton JM, et al
    Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.
    Mult Scler. 2021;27:1284-1292.
    PubMed     Abstract available


  201. CENCIONI MT, Ali R, Nicholas R, Muraro PA, et al
    Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS.
    Mult Scler. 2021;27:1187-1197.
    PubMed     Abstract available


  202. OTALLAH S
    Acute disseminated encephalomyelitis in children and adults: A focused review emphasizing new developments.
    Mult Scler. 2021;27:1153-1160.
    PubMed     Abstract available


    June 2021
  203. SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
    Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
    PubMed     Abstract available


  204. MIZELL R, Chen H, Lambe J, Saidha S, et al
    Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
    Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
    PubMed     Abstract available


  205. BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
    Altered anterior default mode network dynamics in progressive multiple sclerosis.
    Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
    PubMed     Abstract available


  206. HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
    Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
    Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
    PubMed     Abstract available


  207. WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
    High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
    Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
    PubMed     Abstract available


  208. VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
    Acute and chronic synaptic pathology in multiple sclerosis gray matter.
    Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
    PubMed     Abstract available


  209. CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
    Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
    Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
    PubMed     Abstract available


  210. SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
    Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
    Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
    PubMed     Abstract available


  211. KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
    The timed 25-foot walk in a large cohort of multiple sclerosis patients.
    Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
    PubMed     Abstract available


  212. GARJANI A, Hunter R, Law GR, Middleton RM, et al
    Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
    Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
    PubMed     Abstract available


  213. SCHMIERER K, Giovannoni G
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Commentary.
    Mult Scler. 2021;27:1006-1007.
    PubMed    


  214. SCALFARI A
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes.
    Mult Scler. 2021;27:1002-1004.
    PubMed    


  215. CROSS AH, Naismith RT
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No.
    Mult Scler. 2021;27:1004-1005.
    PubMed    


  216. ZACKOWSKI KM, Freeman J, Brichetto G, Centonze D, et al
    Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance.
    Mult Scler. 2021;27:989-1001.
    PubMed     Abstract available


  217. MORROW SA, Conway D, Fuchs T, Wojcik C, et al
    Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
    Mult Scler. 2021;27:1077-1087.
    PubMed     Abstract available


  218. NAYAK S, Sechi E, Flanagan EP, Messina S, et al
    Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
    Mult Scler. 2021;27:1037-1045.
    PubMed     Abstract available


  219. REDER AT
    Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS.
    Mult Scler. 2021;27:1008-1013.
    PubMed     Abstract available


    May 2021
  220. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
    Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
    PubMed     Abstract available


  221. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
    Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
    PubMed     Abstract available


  222. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
    Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
    Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
    PubMed     Abstract available


  223. MCMURRAN CE
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
    Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
    PubMed    


  224. CALVO-BARREIRO L, Clerico M, Espejo C
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
    Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
    PubMed    


  225. HOHLFELD R
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
    Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
    PubMed    


  226. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
    Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
    Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
    PubMed     Abstract available


  227. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
    Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
    Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
    PubMed     Abstract available


  228. DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
    Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
    PubMed     Abstract available


  229. WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
    Staging and stratifying cognitive dysfunction in multiple sclerosis.
    Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
    PubMed     Abstract available


  230. BROWNLEE WJ, Solomon AJ
    Misdiagnosis of multiple sclerosis: Time for action.
    Mult Scler. 2021;27:805-806.
    PubMed    


  231. CORREA DG, de Souza Lima FC, da Cruz Bezerra D, Coutinho AC Junior, et al
    COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence?
    Mult Scler. 2021;27:973-976.
    PubMed     Abstract available


  232. VALENCIA-SANCHEZ C, Flanagan EP
    COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? - Commentary.
    Mult Scler. 2021;27:976-977.
    PubMed    


  233. LONGBRAKE EE, Mao-Draayer Y, Cascione M, Zielinski T, et al
    Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
    Mult Scler. 2021;27:883-894.
    PubMed     Abstract available


  234. CAI MT, Zheng Y, Shen CH, Yang F, et al
    Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
    Mult Scler. 2021;27:871-882.
    PubMed     Abstract available


  235. CACCIAGUERRA L, Rocca MA, Storelli L, Radaelli M, et al
    Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach.
    Mult Scler. 2021;27:841-854.
    PubMed     Abstract available


  236. KASSA RM, Sechi E, Flanagan EP, Kaufmann TJ, et al
    Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.
    Mult Scler. 2021;27:895-902.
    PubMed     Abstract available


    April 2021
  237. HOLLEN C, Rice J, Park M, Yadav V, et al
    Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
    Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
    PubMed     Abstract available


  238. GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
    The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
    Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
    PubMed     Abstract available


  239. VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
    Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
    Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
    PubMed     Abstract available


  240. KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
    Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
    Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
    PubMed     Abstract available


  241. HARRISON AM, Safari R, Mercer T, Picariello F, et al
    Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
    Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
    PubMed     Abstract available


  242. ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
    Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
    Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
    PubMed     Abstract available


  243. ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
    Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
    Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
    PubMed     Abstract available


  244. PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
    Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
    Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
    PubMed     Abstract available


  245. CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
    Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
    Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
    PubMed     Abstract available


  246. CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
    Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
    PubMed     Abstract available


  247. FLEMING KM, Coote SB, Herring MP
    Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
    Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
    PubMed     Abstract available


  248. SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
    Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
    Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
    PubMed     Abstract available


  249. D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
    Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
    Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
    PubMed     Abstract available


  250. CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
    Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
    Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
    PubMed     Abstract available


  251. COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
    Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
    Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
    PubMed     Abstract available


  252. ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
    COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
    PubMed     Abstract available


  253. TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
    A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
    PubMed     Abstract available


  254. BESSING B, Honan CA, van der Mei I, Taylor BV, et al
    Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
    Mult Scler. 2021;27:767-777.
    PubMed     Abstract available


  255. VAN DAM M, Hulst HE, Schoonheim MM
    Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
    Mult Scler. 2021;27:491-493.
    PubMed    


  256. MANCINELLI CR, Scarpazza C, Cordioli C, De Rossi N, et al
    Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mult Scler. 2021;27:790-794.
    PubMed     Abstract available


  257. BIGAUT K, Fabacher T, Kremer L, Ongagna JC, et al
    Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
    Mult Scler. 2021;27:729-741.
    PubMed     Abstract available


  258. KUNCHOK A, Lechner-Scott J, Granella F, Trojano M, et al
    Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
    Mult Scler. 2021;27:695-705.
    PubMed     Abstract available


  259. SECHI E, Messina S, Keegan BM, Buciuc M, et al
    Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
    Mult Scler. 2021;27:667-673.
    PubMed     Abstract available


  260. DATTA P, Ciplea AI, Rewers-Felkins K, Baker T, et al
    Cladribine transfer into human milk: A case report.
    Mult Scler. 2021;27:799-801.
    PubMed     Abstract available


    March 2021
  261. HOWLETT-PRIETO Q, Feng X, Kramer JF, Kramer KJ, et al
    Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis.
    Mult Scler. 2021 Mar 30:13524585211003301. doi: 10.1177/13524585211003301.
    PubMed     Abstract available


  262. THEODORSDOTTIR A, Debrabant B, Magyari M, Kant M, et al
    Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
    Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291.
    PubMed     Abstract available


  263. CREE BA, Cohen JA, Reder AT, Tomic D, et al
    Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
    Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177/13524585211000280.
    PubMed     Abstract available


  264. PORTACCIO E, Fonderico M, Hemmer B, Derfuss T, et al
    Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
    Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177/13524585211005339.
    PubMed     Abstract available


  265. LEE LE, Vavasour IM, Dvorak A, Liu H, et al
    Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
    Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177/13524585211001780.
    PubMed     Abstract available


  266. HARROUD A, Mitchell RE, Richardson TG, Morris JA, et al
    Childhood obesity and multiple sclerosis: A Mendelian randomization study.
    Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177/13524585211001781.
    PubMed     Abstract available


  267. BRIGGS FB, Krill D, Hill E, Conway DS, et al
    Age of hypertension onset in multiple sclerosis patients.
    Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
    PubMed     Abstract available


  268. MASSAROTTI C, Sbragia E, Boffa G, Vercelli C, et al
    Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616.
    PubMed     Abstract available


  269. SCHOONHEIM MM, Douw L, Broeders TA, Eijlers AJ, et al
    The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis.
    Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177/1352458521999274.
    PubMed     Abstract available


  270. MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
    Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
    Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
    PubMed     Abstract available


  271. LORSCHEIDER J
    When does a heap become a heap?
    Mult Scler. 2021;27:329-330.
    PubMed    


  272. BUTZKUEVEN H, Trojano M, Kappos L, Spelman T, et al
    Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP).
    Mult Scler. 2021;27:410-419.
    PubMed     Abstract available


  273. HYUN JW, Kwon YN, Lee HL, Jeong WK, et al
    Recurrence of clinical events at the same anatomical location in patients with MOG antibody-associated disease.
    Mult Scler. 2021;27:449-452.
    PubMed     Abstract available


    February 2021
  274. SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
    Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
    PubMed     Abstract available


  275. FOX RJ, Raska P, Barro C, Karafa M, et al
    Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
    PubMed     Abstract available


  276. MHANNA E, Nouchi A, Louapre C, De Paz R, et al
    Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
    Mult Scler. 2021 Feb 25:1352458521991433. doi: 10.1177/1352458521991433.
    PubMed     Abstract available


  277. COPETTI M, Liu D
    Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
    Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
    PubMed    


  278. HARROUD A, Manousaki D, Butler-Laporte G, Mitchell RE, et al
    The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis.
    Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484.
    PubMed     Abstract available


  279. BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
    Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
    Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
    PubMed     Abstract available


  280. LEMA DOPICO A, Choi S, Hua J, Li X, et al
    Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability.
    Mult Scler. 2021 Feb 18:1352458521994556. doi: 10.1177/1352458521994556.
    PubMed     Abstract available


  281. HARROUD A, Marrie RA, Fitzgerald KC, Salter A, et al
    Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521993075. doi: 10.1177/1352458521993075.
    PubMed     Abstract available


  282. BESSING B, Hussain MA, Claflin SB, Chen J, et al
    Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521994557. doi: 10.1177/1352458521994557.
    PubMed     Abstract available


  283. BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
    Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
    Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
    PubMed     Abstract available


  284. MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
    The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
    Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
    PubMed     Abstract available


  285. VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
    Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
    PubMed     Abstract available


  286. KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
    Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
    PubMed     Abstract available


  287. DAS J, Snowden JA, Burman J, Freedman MS, et al
    Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
    PubMed     Abstract available



  288. Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis.
    Mult Scler. 2021 Feb 2:1352458520978354. doi: 10.1177/1352458520978354.
    PubMed     Abstract available


  289. NYIRENDA MH, Fadda G, Healy LM, Mexhitaj I, et al
    Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
    Mult Scler. 2021 Feb 1:1352458521989090. doi: 10.1177/1352458521989090.
    PubMed     Abstract available


  290. YEH EA
    Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
    Mult Scler. 2021;27:165-166.
    PubMed    


  291. TANASESCU R, Gran B
    Uncovering the underhanded: B-cell depletion therapies and severe viral infections - Commentary on 'Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease'.
    Mult Scler. 2021;27:323-324.
    PubMed    


  292. LUCIANI L, Ninove L, Zandotti C, Chalvignac V, et al
    Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease.
    Mult Scler. 2021;27:320-323.
    PubMed     Abstract available


  293. SALTER A, Stahmann A, Ellenberger D, Fneish F, et al
    Data harmonization for collaborative research among MS registries: A case study in employment.
    Mult Scler. 2021;27:281-289.
    PubMed     Abstract available


  294. SECHI E, Krecke KN, Pittock SJ, Dubey D, et al
    Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.
    Mult Scler. 2021;27:303-308.
    PubMed     Abstract available


    January 2021
  295. MANOUCHEHRINIA A, Kingwell E, Zhu F, Tremlett H, et al
    A multiple sclerosis disease progression measure based on cumulative disability.
    Mult Scler. 2021 Jan 25:1352458520988632. doi: 10.1177/1352458520988632.
    PubMed     Abstract available


  296. JALUSIC KO, Ellenberger D, Rommer P, Stahmann A, et al
    Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
    Mult Scler. 2021 Jan 20:1352458520985118. doi: 10.1177/1352458520985118.
    PubMed     Abstract available


  297. BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
    An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
    Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
    PubMed     Abstract available


  298. ROOS I, Leray E, Frascoli F, Casey R, et al
    Determinants of therapeutic lag in multiple sclerosis.
    Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.
    PubMed     Abstract available


  299. FITZGERALD KC, Damian A, Conway D, Mowry EM, et al
    Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.
    Mult Scler. 2021 Jan 8:1352458520984746. doi: 10.1177/1352458520984746.
    PubMed     Abstract available


  300. GONZALEZ-ESCAMILLA G, Groppa S
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - No.
    Mult Scler. 2021 Jan 6:1352458520969662. doi: 10.1177/1352458520969662.
    PubMed    


  301. SATI P, Reich DS
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers - Commentary.
    Mult Scler. 2021 Jan 6:1352458520981738. doi: 10.1177/1352458520981738.
    PubMed    


  302. LOUAPRE C, Beigneux Y
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - Yes.
    Mult Scler. 2021 Jan 6:1352458520972270. doi: 10.1177/1352458520972270.
    PubMed    


  303. ROLLOT F, Casey R, Leray E, Debouverie M, et al
    Cumulative effects of therapies on disability in relapsing multiple sclerosis.
    Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
    PubMed     Abstract available


  304. MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
    Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
    Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
    PubMed     Abstract available


  305. AMATO MP, Portaccio E, De Meo E
    Understanding the pathophysiology of cognitive changes in MS: A step forward.
    Mult Scler. 2021;27:4-5.
    PubMed    


  306. BISTROM M, Hultdin J, Sundstrom P
    Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
    Mult Scler. 2021;27:161-162.
    PubMed    


  307. AL-ARAJI S, Ciccarelli O
    A possible case of serum sickness after ocrelizumab infusion - Commentary.
    Mult Scler. 2021;27:158-159.
    PubMed     Abstract available


  308. CARNERO CONTENTTI E, Correale J
    Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - Yes.
    Mult Scler. 2021;27:13-15.
    PubMed    


  309. JURYNCZYK M, Messina S, Palace J
    Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD - No.
    Mult Scler. 2021;27:15-16.
    PubMed    


  310. LIBERTINOVA J, Meluzinova E, Nema E, Rockova P, et al
    Elevated D-dimer as an immediate response to alemtuzumab treatment.
    Mult Scler. 2021;27:151-154.
    PubMed     Abstract available


  311. ZHANG J, Giorgio A, Vinciguerra C, Stromillo ML, et al
    Gray matter atrophy cannot be fully explained by white matter damage in patients with MS.
    Mult Scler. 2021;27:39-51.
    PubMed     Abstract available


  312. GEORGE IC, El Mendili MM, Inglese M, Azevedo CJ, et al
    Cerebellar volume loss in radiologically isolated syndrome.
    Mult Scler. 2021;27:130-133.
    PubMed     Abstract available


    December 2020
  313. NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
    Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
    Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
    PubMed     Abstract available


  314. GALLO A, Bisecco A
    Psychological resilience explains functional variability across people with multiple sclerosis - Commentary.
    Mult Scler. 2020 Dec 17:1352458520978213. doi: 10.1177/1352458520978213.
    PubMed    


  315. LEAVITT VM, Kever A
    Psychological resilience explains functional variability across people with multiple sclerosis - Yes.
    Mult Scler. 2020 Dec 17:1352458520972263. doi: 10.1177/1352458520972263.
    PubMed    


  316. PLOUGHMAN M
    Psychological resilience explains functional variability across people with multiple sclerosis - No.
    Mult Scler. 2020 Dec 17:1352458520973633. doi: 10.1177/1352458520973633.
    PubMed    


  317. COMABELLA M, Deutschmann C, Midaglia L, Schierack P, et al
    Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
    Mult Scler. 2020 Dec 17:1352458520980141. doi: 10.1177/1352458520980141.
    PubMed     Abstract available


  318. HYLAND MH, Robb JF
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Yes.
    Mult Scler. 2020 Dec 16:1352458520973640. doi: 10.1177/1352458520973640.
    PubMed    


  319. MOCCIA M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No.
    Mult Scler. 2020 Dec 16:1352458520968815. doi: 10.1177/1352458520968815.
    PubMed    


  320. D'HAESELEER M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Commentary.
    Mult Scler. 2020 Dec 16:1352458520979303. doi: 10.1177/1352458520979303.
    PubMed    


  321. CALABRESI PA, Arnold DL, Sangurdekar D, Singh CM, et al
    Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Mult Scler. 2020 Dec 14:1352458520972573. doi: 10.1177/1352458520972573.
    PubMed     Abstract available


  322. FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
    Serum ceramide levels are altered in multiple sclerosis.
    Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
    PubMed     Abstract available


  323. CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
    Depression in multiple sclerosis across the adult lifespan.
    Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
    PubMed     Abstract available


  324. TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
    Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
    Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
    PubMed     Abstract available


  325. NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
    Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
    Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
    PubMed     Abstract available


  326. JACOBS BM, Smets I, Giovannoni G, Noyce A, et al
    Regarding: Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520969941. doi: 10.1177/1352458520969941.
    PubMed    


  327. BRIGGS F
    Response to Jacobs et al, Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520977027. doi: 10.1177/1352458520977027.
    PubMed    


  328. KOUBIYR I, Deloire M, Brochet B, Besson P, et al
    Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis.
    Mult Scler. 2020 Dec 7:1352458520971807. doi: 10.1177/1352458520971807.
    PubMed     Abstract available


  329. VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
    Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
    Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
    PubMed     Abstract available


  330. RAMANUJAM R, Zhu F, Fink K, Karrenbauer VD, et al
    Accurate classification of secondary progression in multiple sclerosis using a decision tree.
    Mult Scler. 2020 Dec 2:1352458520975323. doi: 10.1177/1352458520975323.
    PubMed     Abstract available


  331. SHAH S
    Real-world evidence: One tweet at a time.
    Mult Scler. 2020;26:1965-1966.
    PubMed    


  332. COETZEE T, Thompson AJ
    Atlas of MS 2020: Informing global policy change.
    Mult Scler. 2020;26:1807-1808.
    PubMed    


  333. PILUTTI LA, Fakolade A
    Rehabilitation should be prescribed acutely in motor relapses - Commentary.
    Mult Scler. 2020;26:1825-1827.
    PubMed    


  334. YONG KP, Kim HJ
    Smelling the danger.
    Mult Scler. 2020;26:1960-1961.
    PubMed    


    November 2020
  335. STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
    Youth with multiple sclerosis have low levels of fitness.
    Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
    PubMed     Abstract available


  336. ROMEO AR, Rowles WM, Schleimer ES, Barba P, et al
    An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
    Mult Scler. 2020 Nov 25:1352458520968814. doi: 10.1177/1352458520968814.
    PubMed     Abstract available


  337. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
    Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
    PubMed     Abstract available


  338. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
    PubMed     Abstract available


  339. IAFFALDANO P, Lucisano G, Patti F, Brescia Morra V, et al
    Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
    Mult Scler. 2020 Nov 19:1352458520974366. doi: 10.1177/1352458520974366.
    PubMed     Abstract available


  340. LARONI A, Schiavetti I, Sormani MP, Uccelli A, et al
    COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
    Mult Scler. 2020 Nov 18:1352458520971817. doi: 10.1177/1352458520971817.
    PubMed     Abstract available


  341. CREE BA, Magnusson B, Rouyrre N, Fox RJ, et al
    Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Nov 18:1352458520971819. doi: 10.1177/1352458520971819.
    PubMed     Abstract available


  342. GLUKHOVSKY L, Kurz D, Brandstadter R, Leavitt VM, et al
    Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments.
    Mult Scler. 2020 Nov 16:1352458520958359. doi: 10.1177/1352458520958359.
    PubMed     Abstract available


  343. PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
    Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
    PubMed     Abstract available


  344. HEITMANN H, Andlauer TFM, Korn T, Muhlau M, et al
    Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.
    Mult Scler. 2020 Nov 12:1352458520972279. doi: 10.1177/1352458520972279.
    PubMed     Abstract available


  345. SACCO R, Braga A, Disanto G, Digesu GA, et al
    Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
    Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
    PubMed     Abstract available


  346. KARIM ME, Pellegrini F, Platt RW, Simoneau G, et al
    The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.
    Mult Scler. 2020 Nov 12:1352458520972557. doi: 10.1177/1352458520972557.
    PubMed     Abstract available


  347. AVILA M, Okai A, Thakolwiboon S, O'Bryan C, et al
    The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study.
    Mult Scler. 2020 Nov 12:1352458520971822. doi: 10.1177/1352458520971822.
    PubMed     Abstract available


  348. WALTON C, King R, Rechtman L, Kaye W, et al
    Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
    Mult Scler. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.
    PubMed     Abstract available


  349. HEDSTROM AK, Olsson T, Alfredsson L
    Cotinine as a measure of smoking in observational studies of multiple sclerosis.
    Mult Scler. 2020 Nov 10:1352458520968803. doi: 10.1177/1352458520968803.
    PubMed     Abstract available


  350. LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
    Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
    Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
    PubMed     Abstract available


  351. BUYUKTURKOGLU K, Zeng D, Bharadwaj S, Tozlu C, et al
    Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.
    Mult Scler. 2020 Nov 4:1352458520958362. doi: 10.1177/1352458520958362.
    PubMed     Abstract available


    October 2020
  352. LOZINSKI BM, Yong VW
    Exercise and the brain in multiple sclerosis.
    Mult Scler. 2020 Oct 30:1352458520969099. doi: 10.1177/1352458520969099.
    PubMed     Abstract available


  353. AFZAL HMR, Luo S, Ramadan S, Lechner-Scott J, et al
    The emerging role of artificial intelligence in multiple sclerosis imaging.
    Mult Scler. 2020 Oct 28:1352458520966298. doi: 10.1177/1352458520966298.
    PubMed     Abstract available


  354. PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
    Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
    Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
    PubMed     Abstract available


  355. STRIK M, Chard DT, Dekker I, Meijer KA, et al
    Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
    Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
    PubMed     Abstract available


  356. KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
    Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
    Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
    PubMed     Abstract available


  357. TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
    Parietal dysfunctional connectivity in depression in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
    PubMed    


  358. JAEGER S, Paul F, Finke C
    Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
    PubMed    


  359. BERMEL RA, Fedler JK, Kaiser P, Novalis C, et al
    Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2020 Oct 15:1352458520964409. doi: 10.1177/1352458520964409.
    PubMed     Abstract available


  360. SIDORE C, Orru V, Cocco E, Steri M, et al
    PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity.
    Mult Scler. 2020 Oct 14:1352458520963937. doi: 10.1177/1352458520963937.
    PubMed     Abstract available


  361. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
    PubMed     Abstract available


  362. CASTELLI L, Quartuccio ME, Ruggieri S, De Giglio L, et al
    'Posture second' strategy predicts disability progression in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963926. doi: 10.1177/1352458520963926.
    PubMed     Abstract available


  363. VEREB D, Toth E, Bozsik B, Kiraly A, et al
    Altered brain network function during attention-modulated visual processing in multiple sclerosis.
    Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
    PubMed     Abstract available


  364. LANGER-GOULD A, Black LJ, Waubant E, Smith JB, et al
    Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility.
    Mult Scler. 2020;26:1476-1485.
    PubMed     Abstract available


  365. CHEN J, Taylor B, Winzenberg T, Palmer AJ, et al
    Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis.
    Mult Scler. 2020;26:1550-1559.
    PubMed     Abstract available


  366. HULST HE, Penner IK
    Cognition and its relation to brain health in patients with MS.
    Mult Scler. 2020;26:1611-1613.
    PubMed    


  367. HOBART J, Giovannoni G
    Cognition and its relation to brain health in patients with MS: Response to letter.
    Mult Scler. 2020;26:1613-1614.
    PubMed    


  368. AZEVEDO CJ, Zamvil SS
    New cases of vasculitis after alemtuzumab.
    Mult Scler. 2020;26:1606-1608.
    PubMed    


    September 2020
  369. PISA M, Chieffo R, Congiu M, Dalla Costa G, et al
    Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520960374. doi: 10.1177/1352458520960374.
    PubMed     Abstract available


  370. FERRE L, Mogavero A, Clarelli F, Moiola L, et al
    Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
    PubMed     Abstract available


  371. BOESEN MS, Blinkenberg M, Thygesen LC, Eriksson F, et al
    School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.
    Mult Scler. 2020 Sep 25:1352458520959673. doi: 10.1177/1352458520959673.
    PubMed     Abstract available


  372. CALVI A, Haider L, Prados F, Tur C, et al
    In vivo imaging of chronic active lesions in multiple sclerosis.
    Mult Scler. 2020 Sep 23:1352458520958589. doi: 10.1177/1352458520958589.
    PubMed     Abstract available


  373. RIVA A, Barcella V, Benatti SV, Capobianco M, et al
    Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.
    Mult Scler. 2020 Sep 17:1352458520952310. doi: 10.1177/1352458520952310.
    PubMed     Abstract available


  374. MOIOLA L, Barcella V, Benatti S, Capobianco M, et al
    The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.
    Mult Scler. 2020 Sep 17:1352458520952311. doi: 10.1177/1352458520952311.
    PubMed     Abstract available


  375. FEYS P, Swinnen E
    Powered exoskeletons for walking in multiple sclerosis.
    Mult Scler. 2020 Sep 15:1352458520958351. doi: 10.1177/1352458520958351.
    PubMed    


  376. WEE SK, Ho CY, Tan SL, Ong CH, et al
    Enhancing quality of life in progressive multiple sclerosis with powered robotic exoskeleton.
    Mult Scler. 2020 Sep 15:1352458520943080. doi: 10.1177/1352458520943080.
    PubMed     Abstract available


  377. CORDANI C, Hidalgo de la Cruz M, Meani A, Valsasina P, et al
    MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes.
    Mult Scler. 2020 Sep 14:1352458520958356. doi: 10.1177/1352458520958356.
    PubMed     Abstract available


  378. ZHANG Y, Taylor BV, Simpson S Jr, Blizzard L, et al
    Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype.
    Mult Scler. 2020 Sep 14:1352458520958369. doi: 10.1177/1352458520958369.
    PubMed     Abstract available


  379. BRIGGS FB
    Nicotinic acetylcholine receptors alpha7 and alpha9 modifies tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Sep 14:1352458520958361. doi: 10.1177/1352458520958361.
    PubMed     Abstract available


  380. KUNCHOK A, Flanagan EP, Krecke KN, Chen JJ, et al
    MOG-IgG1 and co-existence of neuronal autoantibodies.
    Mult Scler. 2020 Sep 10:1352458520951046. doi: 10.1177/1352458520951046.
    PubMed     Abstract available


  381. MARTINO M, Magioncalda P, El Mendili MM, Droby A, et al
    Depression is associated with disconnection of neurotransmitter-related nuclei in multiple sclerosis.
    Mult Scler. 2020 Sep 10:1352458520948214. doi: 10.1177/1352458520948214.
    PubMed     Abstract available


  382. CHEN J, Taylor B, Blizzard L, Simpson-Yap S, et al
    Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis.
    Mult Scler. 2020 Sep 3:1352458520954167. doi: 10.1177/1352458520954167.
    PubMed     Abstract available


  383. YILMAZER C, Lamers I, Solaro C, Feys P, et al
    Clinical perspective on pain in multiple sclerosis.
    Mult Scler. 2020 Sep 3:1352458520952015. doi: 10.1177/1352458520952015.
    PubMed     Abstract available


  384. HAWTON A, Goodwin E, Boddy K, Freeman J, et al
    Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.
    Mult Scler. 2020 Sep 3:1352458520954172. doi: 10.1177/1352458520954172.
    PubMed     Abstract available


  385. JOISTEN N, Proschinger S, Rademacher A, Schenk A, et al
    High-intensity interval training reduces neutrophil-to-lymphocyte ratio in persons with multiple sclerosis during inpatient rehabilitation.
    Mult Scler. 2020 Sep 3:1352458520951382. doi: 10.1177/1352458520951382.
    PubMed     Abstract available


  386. CICCARELLI O, Cohen JA, Thompson A
    Response of the multiple sclerosis community to COVID-19.
    Mult Scler. 2020;26:1134-1136.
    PubMed    


  387. YAM C, Jokubaitis V, Hellwig K, Dobson R, et al
    MS, pregnancy and COVID-19.
    Mult Scler. 2020;26:1137-1146.
    PubMed     Abstract available


  388. MECA-LALLANA V
    COVID-19 will change MS care forever - Yes.
    Mult Scler. 2020;26:1147-1148.
    PubMed    


  389. PREZIOSA P, Rocca MA, Filippi M
    COVID-19 will change MS care forever - No.
    Mult Scler. 2020;26:1149-1151.
    PubMed    


    August 2020
  390. MIDAGLIA L, Otero S, Baro F, Montalban X, et al
    Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy.
    Mult Scler. 2020 Aug 28:1352458520952022. doi: 10.1177/1352458520952022.
    PubMed     Abstract available


  391. DISANTO G, Ripellino P, Riccitelli GC, Sacco R, et al
    De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis.
    Mult Scler. 2020 Aug 25:1352458520952036. doi: 10.1177/1352458520952036.
    PubMed     Abstract available


  392. BOFFA G, Sbragia E, Raiola AM, Varaldo R, et al
    Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases.
    Mult Scler. 2020 Aug 25:1352458520914818. doi: 10.1177/1352458520914818.
    PubMed     Abstract available


  393. SMITH AD, Prokopiusova T, Jones R, Burge T, et al
    Functional electrical stimulation for foot drop in people with multiple sclerosis: The relevance and importance of addressing quality of movement.
    Mult Scler. 2020 Aug 24:1352458520923958. doi: 10.1177/1352458520923958.
    PubMed     Abstract available


  394. SADIGH G, Lava N, Switchenko J, Duszak R Jr, et al
    Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence.
    Mult Scler. 2020 Aug 18:1352458520913977. doi: 10.1177/1352458520913977.
    PubMed     Abstract available


  395. JORDAN AL, Yang J, Fisher CJ, Racke MK, et al
    Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
    Mult Scler. 2020 Aug 18:1352458520949158. doi: 10.1177/1352458520949158.
    PubMed     Abstract available


  396. SEYMAN E, Jones A, Guenette M, Vosoughi R, et al
    Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada.
    Mult Scler. 2020 Aug 11:1352458520948212. doi: 10.1177/1352458520948212.
    PubMed     Abstract available


  397. MOSS BP, Mahajan KR, Bermel RA, Hellisz K, et al
    Multiple sclerosis management during the COVID-19 pandemic.
    Mult Scler. 2020 Aug 10:1352458520948231. doi: 10.1177/1352458520948231.
    PubMed     Abstract available


  398. BROWNLEE WJ
    COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
    Mult Scler. 2020 Aug 7:1352458520948211. doi: 10.1177/1352458520948211.
    PubMed    


  399. WURM H, Attfield K, Iversen AK, Gold R, et al
    Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
    Mult Scler. 2020 Aug 7:1352458520943791. doi: 10.1177/1352458520943791.
    PubMed     Abstract available


  400. DERSCH R, Wehrum T, Fahndrich S, Engelhardt M, et al
    COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
    Mult Scler. 2020 Aug 7:1352458520943783. doi: 10.1177/1352458520943783.
    PubMed     Abstract available


  401. JAWORSKI MG 3RD, Fuchs TA, Dwyer MG, Wojcik C, et al
    Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years.
    Mult Scler. 2020 Aug 6:1352458520946019. doi: 10.1177/1352458520946019.
    PubMed     Abstract available


  402. GERALDES R, Jurynczyk M, Dos Passos GR, Pichler A, et al
    The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease.
    Mult Scler. 2020 Aug 6:1352458520943777. doi: 10.1177/1352458520943777.
    PubMed     Abstract available


  403. GUISSET F, Lolli V, Bugli C, Perrotta G, et al
    The central vein sign in multiple sclerosis patients with vascular comorbidities.
    Mult Scler. 2020 Aug 4:1352458520943785. doi: 10.1177/1352458520943785.
    PubMed     Abstract available


  404. ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
    Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
    Mult Scler. 2020 Aug 4:1352458520946005. doi: 10.1177/1352458520946005.
    PubMed     Abstract available


  405. LIPP I, Foster C, Stickland R, Sgarlata E, et al
    Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: A behavioural and MRI study.
    Mult Scler. 2020 Aug 4:1352458520943788. doi: 10.1177/1352458520943788.
    PubMed     Abstract available


  406. ABBOUD H
    Iatrogenic demyelinating disorders: New insights, new culprits.
    Mult Scler. 2020;26:1129-1130.
    PubMed    


    July 2020
  407. RINGH MV, Hagemann-Jensen M, Needhamsen M, Kullberg S, et al
    Methylome and transcriptome signature of bronchoalveolar cells from multiple sclerosis patients in relation to smoking.
    Mult Scler. 2020 Jul 30:1352458520943768. doi: 10.1177/1352458520943768.
    PubMed     Abstract available



  408. CORRIGENDUM to "Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder".
    Mult Scler. 2020 Jul 24:1352458520945512. doi: 10.1177/1352458520945512.
    PubMed    


  409. SIMPSON-YAP S, Oddy WH, Taylor B, Lucas RM, et al
    High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis.
    Mult Scler. 2020 Jul 23:1352458520943087. doi: 10.1177/1352458520943087.
    PubMed     Abstract available


  410. INOJOSA H, Ziemssen T
    How to reduce the delay of diagnosing secondary progression in multiple sclerosis.
    Mult Scler. 2020 Jul 22:1352458520943799. doi: 10.1177/1352458520943799.
    PubMed    


  411. CONWAY DS, Thompson NR, Meng X, Johnson K, et al
    Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis.
    Mult Scler. 2020 Jul 16:1352458520936214. doi: 10.1177/1352458520936214.
    PubMed     Abstract available


  412. HUBBARD AL, Golla H, Lausberg H
    What's in a name? That which we call Multiple Sclerosis Fatigue.
    Mult Scler. 2020 Jul 16:1352458520941481. doi: 10.1177/1352458520941481.
    PubMed     Abstract available


  413. PEETERS LM, Parciak T, Walton C, Geys L, et al
    COVID-19 in people with multiple sclerosis: A global data sharing initiative.
    Mult Scler. 2020 Jul 14:1352458520941485. doi: 10.1177/1352458520941485.
    PubMed     Abstract available


  414. HIDALGO DE LA CRUZ M, Valsasina P, Gobbi C, Gallo A, et al
    Longitudinal cortical thinning progression differs across multiple sclerosis phenotypes and is clinically relevant: A multicentre study.
    Mult Scler. 2020 Jul 14:1352458520940548. doi: 10.1177/1352458520940548.
    PubMed     Abstract available


  415. BARCELLOS LF, Horton M, Shao X, Bellesis KH, et al
    A validation study for remote testing of cognitive function in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520937385. doi: 10.1177/1352458520937385.
    PubMed     Abstract available


  416. LOONSTRA FC, Hoitsma E, van Kempen ZL, Killestein J, et al
    COVID-19 in multiple sclerosis: The Dutch experience.
    Mult Scler. 2020 Jul 14:1352458520942198. doi: 10.1177/1352458520942198.
    PubMed     Abstract available


  417. STORELLI L, Pagani E, Preziosa P, Filippi M, et al
    Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging.
    Mult Scler. 2020 Jul 14:1352458520938999. doi: 10.1177/1352458520938999.
    PubMed     Abstract available


  418. ABBATEMARCO JR, Griffin A, Jones NG, Hartman J, et al
    Long-term outcomes of intrathecal baclofen in ambulatory multiple sclerosis patients: A single-center experience.
    Mult Scler. 2020 Jul 14:1352458520936912. doi: 10.1177/1352458520936912.
    PubMed     Abstract available


  419. WU P, Li R, Zhang W, Lu H, et al
    Mendelian randomization analysis does not support a role for leptin in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520938990. doi: 10.1177/1352458520938990.
    PubMed    


  420. PINTER D, Khalil M, Pirpamer L, Damulina A, et al
    Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520941474. doi: 10.1177/1352458520941474.
    PubMed     Abstract available


  421. CROTEAU D, Tobenkin A, Brinker A, Kortepeter CM, et al
    Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
    Mult Scler. 2020 Jul 14:1352458520938354. doi: 10.1177/1352458520938354.
    PubMed     Abstract available


  422. GERALDES R
    Two-armed active comparator trials are unethical in pediatric multiple sclerosis - No.
    Mult Scler. 2020 Jul 10:1352458520931784. doi: 10.1177/1352458520931784.
    PubMed    


  423. WAUBANT E
    Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary.
    Mult Scler. 2020 Jul 10:1352458520936243. doi: 10.1177/1352458520936243.
    PubMed    


  424. KRUPP LB, Charvet LE
    Two-armed active comparator trials are unethical in pediatric multiple sclerosis - Yes.
    Mult Scler. 2020 Jul 10:1352458520931796. doi: 10.1177/1352458520931796.
    PubMed    


  425. CHITNIS T, Banwell B, Krupp L, Arnold DL, et al
    Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study.
    Mult Scler. 2020 Jul 7:1352458520936934. doi: 10.1177/1352458520936934.
    PubMed     Abstract available


  426. FITZGERALD KC, Morris B, Soroosh A, Balshi A, et al
    Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue.
    Mult Scler. 2020 Jul 7:1352458520936226. doi: 10.1177/1352458520936226.
    PubMed     Abstract available


  427. HACOHEN Y, Banwell B, Ciccarelli O
    What does first-line therapy mean for paediatric multiple sclerosis in the current era?
    Mult Scler. 2020 Jul 7:1352458520937644. doi: 10.1177/1352458520937644.
    PubMed     Abstract available


  428. KUNCHOK A, Flanagan EP, Snyder M, Saadeh R, et al
    Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD.
    Mult Scler. 2020 Jul 7:1352458520933884. doi: 10.1177/1352458520933884.
    PubMed     Abstract available


  429. BSTEH G, Berek K, Hegen H, Altmann P, et al
    Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis.
    Mult Scler. 2020 Jul 2:1352458520935724. doi: 10.1177/1352458520935724.
    PubMed     Abstract available


  430. THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
    Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
    Mult Scler. 2020 Jul 2:1352458520936231. doi: 10.1177/1352458520936231.
    PubMed     Abstract available


  431. ARRAMBIDE G
    MOG-antibody-associated disease-getting the whole picture.
    Mult Scler. 2020;26:1000-1001.
    PubMed    


    June 2020
  432. FEINSTEIN A, Meza C, Stefan C, Staines WR, et al
    Discontinuing cannabis improves depression in people with multiple sclerosis: A short report.
    Mult Scler. 2020 Jun 26:1352458520934070. doi: 10.1177/1352458520934070.
    PubMed     Abstract available


  433. SIGNORI A, Boffa G, Bovis F, Mariottini A, et al
    Prevalence of disability improvement as a potential outcome for multiple sclerosis trials.
    Mult Scler. 2020 Jun 26:1352458520936236. doi: 10.1177/1352458520936236.
    PubMed     Abstract available



  434. Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis.
    Mult Scler. 2020 Jun 26:1352458520924594. doi: 10.1177/1352458520924594.
    PubMed     Abstract available


  435. MEHNDIRATTA A, Treaba CA, Barletta V, Herranz E, et al
    Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI.
    Mult Scler. 2020 Jun 25:1352458520932804. doi: 10.1177/1352458520932804.
    PubMed     Abstract available


  436. BOVE R, Rowles W, Zhao C, Anderson A, et al
    A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study.
    Mult Scler. 2020 Jun 25:1352458520930371. doi: 10.1177/1352458520930371.
    PubMed     Abstract available


  437. WIENDL H, Spelman T, Butzkueven H, Kappos L, et al
    Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
    Mult Scler. 2020 Jun 24:1352458520926869. doi: 10.1177/1352458520926869.
    PubMed     Abstract available


  438. GLUKHOVSKY L, Brandstadter R, Leavitt VM, Krieger S, et al
    Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis.
    Mult Scler. 2020 Jun 22:1352458520922830. doi: 10.1177/1352458520922830.
    PubMed     Abstract available


  439. SASTRE-GARRIGA J, Tintore M, Montalban X
    Keeping standards of multiple sclerosis care through the COVID-19 pandemic.
    Mult Scler. 2020 Jun 19:1352458520931785. doi: 10.1177/1352458520931785.
    PubMed    


  440. LEVIN SN, Ezuma C, Levine L, Vargas WS, et al
    Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.
    Mult Scler. 2020 Jun 19:1352458520927631. doi: 10.1177/1352458520927631.
    PubMed    


  441. GHEZZI A, Banwell B, Bar-Or A, Chitnis T, et al
    Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.
    Mult Scler. 2020 Jun 19:1352458520932798. doi: 10.1177/1352458520932798.
    PubMed     Abstract available


  442. BHARGAVA P, Nogueras-Ortiz C, Kim S, Delgado-Peraza F, et al
    Synaptic and complement markers in extracellular vesicles in multiple sclerosis.
    Mult Scler. 2020 Jun 17:1352458520924590. doi: 10.1177/1352458520924590.
    PubMed     Abstract available


  443. RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
    Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
    Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
    PubMed     Abstract available


  444. YAVARPOUR-BALI H, Ghasemi-Kasman M
    The role of inflammasomes in multiple sclerosis.
    Mult Scler. 2020 Jun 16:1352458520932776. doi: 10.1177/1352458520932776.
    PubMed     Abstract available


  445. GHEZZI A, Amato MP, Edan G, Hartung HP, et al
    The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
    Mult Scler. 2020 Jun 16:1352458520930620. doi: 10.1177/1352458520930620.
    PubMed     Abstract available


  446. LE M, Malpas C, Sharmin S, Horakova D, et al
    Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
    Mult Scler. 2020 Jun 15:1352458520926955. doi: 10.1177/1352458520926955.
    PubMed     Abstract available


  447. IACOBAEUS E, Arrambide G, Pia Amato M, Derfuss T, et al
    Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
    Mult Scler. 2020 Jun 12:1352458520925369. doi: 10.1177/1352458520925369.
    PubMed     Abstract available


  448. ARRAMBIDE G, Iacobaeus E, Amato MP, Derfuss T, et al
    Aggressive multiple sclerosis (2): Treatment.
    Mult Scler. 2020 Jun 12:1352458520924595. doi: 10.1177/1352458520924595.
    PubMed     Abstract available


  449. LIZAK N, Hodgkinson S, Butler E, Lechner-Scott J, et al
    Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
    Mult Scler. 2020 Jun 12:1352458520921087. doi: 10.1177/1352458520921087.
    PubMed     Abstract available


  450. POLAT DUNYA C, Tulek Z, Kurtuncu M, Panicker JN, et al
    Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder.
    Mult Scler. 2020 Jun 9:1352458520926666. doi: 10.1177/1352458520926666.
    PubMed     Abstract available


  451. SOLARI A, Oliver D
    Palliative care in multiple sclerosis: European guideline.
    Mult Scler. 2020 Jun 9:1352458520926467. doi: 10.1177/1352458520926467.
    PubMed    


  452. XU Y, Hiyoshi A, Brand JS, Smith KA, et al
    Higher body mass index at ages 16 to 20 years is associated with increased risk of a multiple sclerosis diagnosis in subsequent adulthood among men.
    Mult Scler. 2020 Jun 8:1352458520928061. doi: 10.1177/1352458520928061.
    PubMed     Abstract available


  453. BROWN J, Quattrochi B, Everett C, Hong BY, et al
    Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis.
    Mult Scler. 2020 Jun 8:1352458520928301. doi: 10.1177/1352458520928301.
    PubMed     Abstract available


  454. CELIUS EG
    Breastfeeding and treatment of multiple sclerosis.
    Mult Scler. 2020 Jun 8:1352458520931786. doi: 10.1177/1352458520931786.
    PubMed    


  455. PIHL-JENSEN G, Wanscher B, Frederiksen JL
    Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis.
    Mult Scler. 2020 Jun 8:1352458520917924. doi: 10.1177/1352458520917924.
    PubMed     Abstract available


  456. ROJAS JI, Patrucco L, Alonso R, Garcea O, et al
    Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
    Mult Scler. 2020 Jun 2:1352458520924586. doi: 10.1177/1352458520924586.
    PubMed     Abstract available


  457. OH J, Chen M, Cybulsky K, Suthiphosuwan S, et al
    Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis.
    Mult Scler. 2020 Jun 1:1352458520923970. doi: 10.1177/1352458520923970.
    PubMed     Abstract available


  458. COSTELLO F, Petzold A
    Weighting evidence in MS: Obesity and neurodegeneration.
    Mult Scler. 2020;26:748-750.
    PubMed    


  459. BOYKO A
    Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group.
    Mult Scler. 2020;26:869-870.
    PubMed    


  460. DE STEFANO N
    Response to Dr Boyko's letter: 'Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as highly MS-risk group'.
    Mult Scler. 2020;26:871.
    PubMed    


  461. VAN DER WALT A
    Addressing the treatment gap in MS-associated tremor: A new door opens.
    Mult Scler. 2020;26:858.
    PubMed    


    May 2020
  462. VARGAS WS, Noble KG, Banwell B, De Jager P, et al
    The educational impact of childhood-onset multiple sclerosis: Why assessing academic achievement is imperative.
    Mult Scler. 2020 May 28:1352458520923946. doi: 10.1177/1352458520923946.
    PubMed     Abstract available


  463. VON WYL V, Benkert P, Moser A, Lorscheider J, et al
    Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
    Mult Scler. 2020 May 28:1352458520918489. doi: 10.1177/1352458520918489.
    PubMed     Abstract available


  464. CARANDINI T, Pietroboni AM, Sacchi L, De Riz MA, et al
    Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
    Mult Scler. 2020 May 28:1352458520926459. doi: 10.1177/1352458520926459.
    PubMed    


  465. PASQUA G, Tommasin S, Bharti K, Ruggieri S, et al
    Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis.
    Mult Scler. 2020 May 28:1352458520922770. doi: 10.1177/1352458520922770.
    PubMed     Abstract available


  466. AYRIGNAC X, Larochelle C, Keezer M, Roger E, et al
    Frailty in ageing persons with multiple sclerosis.
    Mult Scler. 2020 May 27:1352458520923945. doi: 10.1177/1352458520923945.
    PubMed     Abstract available


  467. CORONADO I, Gabr RE, Narayana PA
    Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis.
    Mult Scler. 2020 May 22:1352458520921364. doi: 10.1177/1352458520921364.
    PubMed     Abstract available


  468. WANG FM, Davis MF, Briggs FB
    Predicting self-reported depression after the onset of multiple sclerosis using genetic and non-genetic factors.
    Mult Scler. 2020 May 18:1352458520921073. doi: 10.1177/1352458520921073.
    PubMed     Abstract available


  469. BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
    Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
    Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
    PubMed    


  470. VALBURG C, Sonti A, Stern JN, Najjar S, et al
    Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review.
    Mult Scler. 2020 May 14:1352458520923955. doi: 10.1177/1352458520923955.
    PubMed     Abstract available


  471. KILJAN S, Preziosa P, Jonkman LE, van de Berg WD, et al
    Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study.
    Mult Scler. 2020 May 11:1352458520918978. doi: 10.1177/1352458520918978.
    PubMed     Abstract available


  472. GHARAKHANLOU R, Wesselmann L, Rademacher A, Lampit A, et al
    Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials.
    Mult Scler. 2020 May 11:1352458520917935. doi: 10.1177/1352458520917935.
    PubMed     Abstract available


  473. LUNEMANN JD, Diaz-Diaz J, Stankoff B, Young C, et al
    Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019).
    Mult Scler. 2020 May 4:1352458520918377. doi: 10.1177/1352458520918377.
    PubMed     Abstract available


  474. BOSE G, Thebault S, Rush CA, Atkins HL, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Mult Scler. 2020 May 4:1352458520917936. doi: 10.1177/1352458520917936.
    PubMed     Abstract available


  475. LAMBE J, Saidha S, Bermel RA
    Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials.
    Mult Scler. 2020;26:624-639.
    PubMed     Abstract available


  476. HARTUNG HP, Mares J, Barnett MH
    Alemtuzumab: Rare serious adverse events of a high-efficacy drug.
    Mult Scler. 2020;26:737-740.
    PubMed    


  477. KRIEGER SC, Sumowski JF
    Toward biologically meaningful categories of MS-related fatigue.
    Mult Scler. 2020;26:620-621.
    PubMed    


  478. PROSCHMANN U, Sehr T, Akgun K, Ziemssen T, et al
    Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".
    Mult Scler. 2020;26:741-742.
    PubMed    


    April 2020
  479. FOX E, Lovett-Racke AE, Gormley M, Liu Y, et al
    A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
    Mult Scler. 2020 Apr 30:1352458520918375. doi: 10.1177/1352458520918375.
    PubMed     Abstract available


  480. KALB R, Brown TR, Coote S, Costello K, et al
    Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.
    Mult Scler. 2020 Apr 23:1352458520915629. doi: 10.1177/1352458520915629.
    PubMed     Abstract available


  481. AHRABIAN D, Neill L, Bell R, Leary SM, et al
    Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519855725. doi: 10.1177/1352458519855725.
    PubMed     Abstract available


  482. FILIPPATOU AG, Lambe J, Sotirchos ES, Fitzgerald KC, et al
    Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519900942. doi: 10.1177/1352458519900942.
    PubMed     Abstract available


  483. UHER T, McComb M, Galkin S, Srpova B, et al
    Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
    Mult Scler. 2020 Apr 7:1352458520912379. doi: 10.1177/1352458520912379.
    PubMed     Abstract available


  484. YUSUF F, Wijnands JM, Kingwell E, Zhu F, et al
    Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
    Mult Scler. 2020 Apr 6:1352458520908163. doi: 10.1177/1352458520908163.
    PubMed     Abstract available


  485. BELBASIS L, Bellou V, Evangelou E, Tzoulaki I, et al
    Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.
    Mult Scler. 2020;26:397-404.
    PubMed     Abstract available


  486. SOLOMON AJ
    Progress towards a diagnostic biomarker for MS: Central vein sign.
    Mult Scler. 2020;26:394-396.
    PubMed    


  487. LEVY M
    Expanding the spectrum of MOG antibody disease.
    Mult Scler. 2020;26:515-516.
    PubMed    


    March 2020
  488. HEALY BC, Barker L, Bakshi R, Benedict RHB, et al
    Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
    Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439.
    PubMed     Abstract available


  489. TREMLETT H, Marrie RA
    The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities.
    Mult Scler. 2020 Mar 31:1352458520914844. doi: 10.1177/1352458520914844.
    PubMed     Abstract available


  490. MOTL RW, Sandroff BM, Benedict RH, Hubbard EM, et al
    Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
    Mult Scler. 2020 Mar 31:1352458520914822. doi: 10.1177/1352458520914822.
    PubMed     Abstract available


  491. DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
    Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
    PubMed     Abstract available


  492. JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
    Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
    Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
    PubMed     Abstract available


  493. DADAR M, Narayanan S, Arnold DL, Collins DL, et al
    Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
    PubMed     Abstract available


  494. OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
    Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
    PubMed     Abstract available


  495. PEREZ T, Rico A, Boutiere C, Maarouf A, et al
    Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
    Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
    PubMed     Abstract available


  496. SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
    Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
    Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
    PubMed     Abstract available


  497. SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
    Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
    Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
    PubMed     Abstract available


  498. BERTOLI M, Tecchio F
    Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
    Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
    PubMed     Abstract available


  499. DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
    Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
    Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
    PubMed     Abstract available


  500. NG HS, Kingwell E, Zhu F, Zhang T, et al
    Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
    Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
    PubMed     Abstract available


  501. ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
    Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
    Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
    PubMed     Abstract available


  502. FUJIHARA K
    MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - Commentary.
    Mult Scler. 2020;26:276-278.
    PubMed    


  503. LEITE MI, Sato DK
    MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
    Mult Scler. 2020;26:272-274.
    PubMed    


  504. COBO-CALVO A, Marignier R
    MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
    Mult Scler. 2020;26:274-276.
    PubMed    


  505. DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
    Spontaneous multiple cervical artery dissections after alemtuzumab.
    Mult Scler. 2020;26:381-383.
    PubMed     Abstract available


  506. CHIARAVALLOTI ND, Moore NB, DeLuca J
    The efficacy of the modified Story Memory Technique in progressive MS.
    Mult Scler. 2020;26:354-362.
    PubMed     Abstract available


  507. ROSSOR T, Benetou C, Wright S, Duignan S, et al
    Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis.
    Mult Scler. 2020;26:333-342.
    PubMed     Abstract available


    February 2020
  508. POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
    Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
    Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
    PubMed     Abstract available


  509. FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
    Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
    Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
    PubMed     Abstract available


  510. HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
    ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
    PubMed     Abstract available


  511. BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
    Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
    PubMed     Abstract available


  512. MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
    Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
    Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
    PubMed     Abstract available


  513. MCKEON A, Zekeridou A
    Autoimmune encephalitis management: MS centers and beyond.
    Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
    PubMed     Abstract available


  514. SON M, McEwan L, Ubaidat M, Bovell K, et al
    Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
    PubMed     Abstract available


  515. BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
    Leptin levels are associated with multiple sclerosis risk.
    Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
    PubMed     Abstract available


  516. MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
    Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
    PubMed     Abstract available


  517. THOMPSON AJ, Cohen JA, Kim HJ, Geurts J, et al
    MSJ 2020 - Editorial comment.
    Mult Scler. 2020;26:134.
    PubMed    


  518. LUBLIN F
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Commentary.
    Mult Scler. 2020;26:163-164.
    PubMed    


  519. SORMANI MP
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.
    Mult Scler. 2020;26:161-162.
    PubMed    


  520. KALINCIK T
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
    Mult Scler. 2020;26:159-161.
    PubMed    


    January 2020
  521. CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
    A critical analysis of helminth immunotherapy in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
    PubMed     Abstract available


  522. BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
    Recovery of cognitive function after relapse in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
    PubMed     Abstract available


  523. CARNERO CONTENTTI E, Giachello S, Correale J
    Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
    Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
    PubMed     Abstract available


  524. SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
    Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
    PubMed     Abstract available


  525. CORTESE R, Tur C, Prados F, Schneider T, et al
    Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
    PubMed     Abstract available


  526. SALTER A, Fox RJ, Tyry T, Cutter G, et al
    New applications for independent activities of daily living in measuring disability in multiple sclerosis.
    Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
    PubMed     Abstract available


  527. WARNKE C, Hartung HP
    Big data in MS-What can we learn from large international observational studies such as MSBase?
    Mult Scler. 2020;26:4-5.
    PubMed    


  528. REDDEL SW
    Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.
    Mult Scler. 2020;26:126-127.
    PubMed    


  529. VUKUSIC S, Casey R, Rollot F, Brochet B, et al
    Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.
    Mult Scler. 2020;26:118-122.
    PubMed     Abstract available


  530. MELI R, Roccatagliata L, Capello E, Bruschi N, et al
    Ecological impact of isolated cognitive relapses in MS.
    Mult Scler. 2020;26:114-117.
    PubMed     Abstract available


  531. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders.
    Mult Scler. 2020;26:128-129.
    PubMed    


    December 2019
  532. CROUSE DL, Foroughi I, Gupta N
    Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
    Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
    PubMed     Abstract available


  533. COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
    High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
    Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
    PubMed     Abstract available


  534. KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
    Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
    Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
    PubMed     Abstract available


  535. KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
    Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
    Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
    PubMed     Abstract available


  536. HOLTON KF, Kirkland AE
    Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
    Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
    PubMed     Abstract available


  537. RAHNAMA'I MS
    Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
    Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
    PubMed     Abstract available


  538. BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
    Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
    Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
    PubMed     Abstract available


    November 2019
  539. GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
    Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
    Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
    PubMed     Abstract available


  540. WALLACH AI, Waltz M, Casper TC, Aaen G, et al
    Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
    Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
    PubMed     Abstract available


  541. LI CMF, Hung PS, Chu PP, Tohyama S, et al
    Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
    Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
    PubMed     Abstract available


  542. COMI G, Alroughani R, Boster AL, Bass AD, et al
    Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
    Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
    PubMed     Abstract available


  543. KIM JE, Park SH, Han K, Kim HJ, et al
    Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
    Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
    PubMed     Abstract available


  544. BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
    Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
    Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
    PubMed     Abstract available


  545. BAETGE SJ, Filser M, Renner A, Ullrich S, et al
    On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
    Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
    PubMed     Abstract available


  546. BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
    Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
    PubMed     Abstract available


  547. PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
    Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
    Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
    PubMed     Abstract available


  548. CORDANI C, Valsasina P, Preziosa P, Meani A, et al
    Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
    Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
    PubMed     Abstract available


  549. COLLORONE S, Cawley N, Grussu F, Prados F, et al
    Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
    Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
    PubMed     Abstract available


  550. NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
    Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
    PubMed     Abstract available


  551. KUHLE J, Plavina T, Barro C, Disanto G, et al
    Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
    PubMed     Abstract available


  552. VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
    Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
    Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
    PubMed     Abstract available


    October 2019
  553. RYAN JM, Fortune J, Stennett A, Kilbride C, et al
    Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
    Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
    PubMed     Abstract available


  554. LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
    eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
    PubMed     Abstract available


  555. ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
    Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
    PubMed     Abstract available


  556. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
    PubMed     Abstract available


  557. JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
    Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
    Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
    PubMed     Abstract available


  558. JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
    Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
    PubMed     Abstract available


  559. DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
    Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
    Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
    PubMed     Abstract available


  560. GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
    Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
    Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
    PubMed     Abstract available


  561. ZECCA C, Bovis F, Novi G, Capobianco M, et al
    Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
    PubMed     Abstract available


    July 2019
  562. KANG Y, Gauthier SA
    PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.
    Mult Scler. 2019;25:1090-1091.
    PubMed    


    June 2019
  563. GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
    T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
    Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
    PubMed     Abstract available


  564. ZEYDAN B, Kantarci OH
    MS progression is predominantly driven by age-related mechanisms - Commentary.
    Mult Scler. 2019;25:906-908.
    PubMed    


    April 2019
  565. MANOUSAKI D, Richards JB
    Vitamin D deficiency is an etiological factor for MS - Yes.
    Mult Scler. 2019;25:637-639.
    PubMed    


  566. LANGER-GOULD A, Lucas RM
    Vitamin D deficiency is an etiological factor for MS - No.
    Mult Scler. 2019;25:639-641.
    PubMed    


  567. WILLIAMS T, Chataway J
    Immune-mediated encephalitis with daclizumab: The final nail.
    Mult Scler. 2019;25:753-754.
    PubMed     Abstract available


  568. THOUVENOT E, Hinsinger G, Demattei C, Uygunoglu U, et al
    Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
    Mult Scler. 2019;25:669-677.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: